CDK4 and endometrial cancer: In endometrial cancer, the majority of CCND1 mutations were located in the carboxy-terminal region of cyclin D1 (70%, 21 of 30 endometrial cancers), likely resulting in cyclin D1 oncogenic activation of cyclin D1-CDK4/6 complexes and gain of function.